• DOI:10.1038/nrd3681
• Corpus ID: 3344476

Diagnosing the decline in pharmaceutical R&D efficiency

@article{Scannell2012DiagnosingTD,
  title={Diagnosing the decline in pharmaceutical R\&D efficiency},
  author={Jack W. Scannell and Alex Blanckley and Helen Boldon and Brian Warrington},
  journal={Nature Reviews Drug Discovery},
  year={2012},
  volume={11},
  pages={191-200}
}

• J. Scannell, Alex Blanckley, +1 author B. Warrington
• Published 1 March 2012
• Political Science
• Nature Reviews Drug Discovery

The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (R&D). Yet the number of new drugs approved per billion US dollars spent on R&D has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining R&D efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research–brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in R&D efficiency.